Latest Strategy News

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing of its investigational drug PYC-001 for Autosomal Dominant Optic Atrophy from single to multiple doses, marking a key step in its clinical development.

Desert Metals Limited has launched a fully underwritten entitlement offer to raise approximately $325,000 through new options, aiming to fund ongoing exploration at its gold prospects in Côte d’Ivoire.

Fat Prophets Global Contrarian Fund (ASX: FPC) has disclosed the Dividend Reinvestment Plan (DRP) price for its six-month dividend ending December 2025, applying a 2.5% discount to the volume weighted average price, resulting in a DRP price of AUD 1.35 per share.

Asara Resources (ASX:AS1) is pushing ahead at its Kada Gold Project in Guinea’s prolific Siguiri Basin, boasting a 923,000-ounce gold resource and launching expansive 2026 drilling campaigns aimed at significantly growing both Indicated and Inferred categories.

Scott Technology delivered a solid HY26 with 7% EBITDA growth to $13 million, driven by strong performances in Materials Handling and Mining, offsetting softness in Protein and Appliances. Forward work rose to $177 million, underpinning expectations for a stronger second half despite geopolitical uncertainties.

Andromeda Metals has wrapped up the Early Works phase at its Great White Project, setting the stage for construction and trimming the equity funding needed for the next development stage to about $40 million.

Ovanti Limited has raised $5.27 million through a discounted placement, aiming to accelerate its global Buy Now Pay Later platform and Super App development with AI integration and merchant expansion.

Charger Metals has confirmed significant extensions to spodumene mineralisation at its Medcalf project, with drilling pushing lithium-bearing pegmatites to 600-700m depth and along strike. The company anticipates a substantial resource upgrade following assay results due in the coming weeks.

XRF Scientific posted a 13.8% jump in March quarter revenue to $15.8 million, led by strong international sales and new product shipments. The newly operational India office marks a strategic expansion, setting the stage for further growth.

Noxopharm appoints its Chief Scientific Officer Dr Olivier Laczka as CEO, aiming to capitalise on recent clinical successes and expand the Sofra™ technology’s reach in autoimmune and oncology markets.

Immutep Limited has won FDA Orphan Drug Designation for its immunotherapy eftilagimod alfa in treating soft tissue sarcoma, opening regulatory incentives and potential market exclusivity. This follows encouraging Phase II data despite recent Phase III trial setbacks.

WhiteHawk Limited has raised A$1.5 million through a share placement to fund integration and growth of its newly acquired Quixxi Clarity AI platform, marking a strategic push into the AI governance market.